AAP
MRNA icon

Arax Advisory Partners’s Moderna MRNA Stock Holding History

Arax Advisory Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-274
Closed -$8.08K – 4140
2025
Q4 		$8.08K Buy
+274
New +$7.44K ﹤0.01% 2587
2025
Q3 		– Sell
-51
Closed -$1.41K – 4055
2025
Q2 		$1.41K Sell
51
-8
-14% -$211 ﹤0.01% 2669
2025
Q1 		$1.67K Sell
59
-262
-82% -$9.3K ﹤0.01% 2122
2024
Q4 		$13.3K Buy
321
+219
+215% +$10.5K ﹤0.01% 1377
2024
Q3 		$6.82K Hold
102
– – ﹤0.01% 1574
2024
Q2 		$12.1K Sell
102
-198
-66% -$25.1K ﹤0.01% 1174
2024
Q1 		$32K Buy
+300
New +$30.2K ﹤0.01% 579
2021
Q3 		– Sell
-500
Closed -$117K – 1048
2021
Q2 		$117K Buy
+500
New +$89.4K 0.02% 306

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return